Interpretation of patient-specific ex vivo immunotherapy response for ovarian cancer - VitroScan presents @ the AACR-NCI-EORTC meeting 2023

14 October 2023

At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 11-15, 2023, in Boston, Willemijn Vader presented VitroScans most recent results on 'Interpretation of patient-specific ex vivo immunotherapy response for ovarian cancer' that were generated in the TUMOVCA trial led by Cor de Kroon, Judith Kroep (Leiden University Medical Center), Nelleke Ottevanger, and Anne van Altena (Radboudumc).
The data were generated in collaboration with our partners in the 3D SCREEN Eurostars project: Crown Bioscience, Sciomics - Enabling Precision Medicine, AnaPath Services

Find the poster via VitroScan's publications page